420
Participants
Start Date
November 30, 2022
Primary Completion Date
June 27, 2024
Study Completion Date
June 27, 2024
Octaplex
Prothrombin complex concentrate
Frozen Plasma Product, Human
If additional treatment is required after the maximum dose of IMP is administered or the treatment period has elapsed, patients in both groups will receive frozen plasma
Duke University Health System, Durham
University of Oklahoma Health Sciences Center, Oklahoma City
Royal Columbian Hospital, New Westminster
University of British Columbia and Vancouver Coastal Health Authority, Vancouver
Hamilton Health Sciences Corporation, Hamilton
Kingston General Hospital, Kingston
London Health Sciences, London
University of Ottawa Heart Institute, Ottawa
Sunnybrook Hospital, Toronto
St. Michael's Hospital, Toronto
Toronto General Hospital, Toronto
Montreal Heart Institute, Montreal
Quebec Laval, Québec
Lead Sponsor
Octapharma
INDUSTRY